Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Group D Clear all
Completed Not applicable Interventional

Patient Centered Home Exercise Program for Peripheral Artery Disease

NCT02462824
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Home-based exercise intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03251482
View directory record Official record
Conditions
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions
JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Computerized Alcohol Misuse Intervention System for Health Care

NCT02368899
View directory record Official record
Conditions
Alcoholism
Interventions
Computerized Alcohol Misuse Intervention, Attention Control (AC)
Other
Lead sponsor
Research Circle Associates, LLC
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gender-Responsive Drug Use Treatment for Juvenile Justice Girls

NCT02293057
View directory record Official record
Conditions
Drug Use
Interventions
VOICES Group, Girl Health Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 24 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Pilot Study of Mothers and Babies Online in Home Visiting

NCT05714956
View directory record Official record
Conditions
Perinatal Depression
Interventions
Mothers and Babies Online (eMB)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Joliet, Illinois • Chariton, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

NCT00203957
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Bulevirtide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Not applicable Interventional Results available

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

NCT01263028
View directory record Official record
Conditions
Chronic Kidney Disease Stages 3-5
Interventions
Ergocalciferol supplementation
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken

NCT05248737
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
DHA/EPA fortified chicken plus Placebo, non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement, non-DHA bio-enhanced chicken plus supplement DHA Omega-3, 25(OH)D bioenhanced chicken and eggs plus placebo, Dietary Supplement: DHA/EPA fortified eggs plus Placebo, non-DHA bio-enhanced eggs plus supplement DHA Omega-3, non-25(OH)D fortified chicken/eggs plus placebo
Dietary Supplement · Other
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Withdrawn Phase 4 Interventional

Psychopharmacological Treatment of Emotional Distress

NCT06133114
View directory record Official record
Conditions
Suicide Crisis Syndrome, Psychological Distress
Interventions
Clonazepam, Olanzapine, Buprenorphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

NCT07369063
View directory record Official record
Conditions
Graves Disease, Graves' Disease, Hyperthyroidism
Interventions
Ergocalciferol 50,000 IU, Methimazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
9 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT04868903
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use

NCT00876941
View directory record Official record
Conditions
Drug Usage, Drug Abuse, Drug Dependence
Interventions
Standard Brief Intervention, Enhanced Brief Intervention, Control: Information and Feedback
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Early Phase 1 Interventional

Effect of Vitamin D After Application With Valchlor

NCT02968446
View directory record Official record
Conditions
Skin Irritation
Interventions
4 placebo, 4 Vitamin D, Valchlor
Dietary Supplement · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

NCT01746303
View directory record Official record
Conditions
Age-related Memory Disorders, Mood Disorders
Interventions
Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder
Dietary Supplement · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
62 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

NCT01138475
View directory record Official record
Conditions
Gastric Bypass, Parathyroid Hormone
Interventions
Paricalcitol, Cholecalciferol, Placebo
Drug
Lead sponsor
Kerstyn C. Zalesin, M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed No phase listed Observational

ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0

NCT01539629
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac pacing
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Davenport, Iowa • Yardley, Pennsylvania • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

Daily Eating Patterns for Total Health Study

NCT06455995
View directory record Official record
Conditions
Obesity
Interventions
DEPTH, DEPTH-Morning, DEPTH-Evening
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
25 Years to 60 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 7, 2026, 11:02 AM EDT